Frontage Holdings Corp
HKEX:1521

Watchlist Manager
Frontage Holdings Corp Logo
Frontage Holdings Corp
HKEX:1521
Watchlist
Price: 0.99 HKD Market Closed
Market Cap: HK$2B

Frontage Holdings Corp
Other Long-Term Assets

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
|
See Also

Frontage Holdings Corp
Other Long-Term Assets Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Other Long-Term Assets CAGR 3Y CAGR 5Y CAGR 10Y
Frontage Holdings Corp
HKEX:1521
Other Long-Term Assets
$11.4m
CAGR 3-Years
17%
CAGR 5-Years
14%
CAGR 10-Years
N/A
Thermo Fisher Scientific Inc
NYSE:TMO
Other Long-Term Assets
$6B
CAGR 3-Years
15%
CAGR 5-Years
19%
CAGR 10-Years
19%
Danaher Corp
NYSE:DHR
Other Long-Term Assets
$3B
CAGR 3-Years
-5%
CAGR 5-Years
9%
CAGR 10-Years
11%
Waters Corp
NYSE:WAT
Other Long-Term Assets
$307.8m
CAGR 3-Years
17%
CAGR 5-Years
16%
CAGR 10-Years
8%
Agilent Technologies Inc
NYSE:A
Other Long-Term Assets
$886m
CAGR 3-Years
8%
CAGR 5-Years
9%
CAGR 10-Years
14%
IQVIA Holdings Inc
NYSE:IQV
Other Long-Term Assets
$862m
CAGR 3-Years
13%
CAGR 5-Years
12%
CAGR 10-Years
19%
No Stocks Found

Frontage Holdings Corp
Glance View

Frontage Holdings Corp. engages in the provision of research and analytical and development services throughout the drug discovery and development process. The company is headquartered in Exton, Pennsylvania. The company went IPO on 2019-05-30. Its segments include North America and the People’s Republic of China (PRC). Its North America segment, including laboratory testing, chemistry, manufacturing and control (CMC), preclinical research and chemistry services in the United States of America and Canada. Its PRC segment including laboratory testing, CMC, preclinical research, bioequivalence clinical and chemistry services in the PRC. Its preclinical research includes drug metabolism and pharmacokinetic (DMPK), safety, chemical and toxicology, and laboratory testing, including bioanalytical and biologics, and central laboratory. Its services and solutions include drug candidate evaluation, product development, clinical services and central laboratory and testing services.

Intrinsic Value
1.15 HKD
Undervaluation 14%
Intrinsic Value
Price HK$0.99

See Also

What is Frontage Holdings Corp's Other Long-Term Assets?
Other Long-Term Assets
11.4m USD

Based on the financial report for Dec 31, 2025, Frontage Holdings Corp's Other Long-Term Assets amounts to 11.4m USD.

What is Frontage Holdings Corp's Other Long-Term Assets growth rate?
Other Long-Term Assets CAGR 5Y
14%

Over the last year, the Other Long-Term Assets growth was 35%. The average annual Other Long-Term Assets growth rates for Frontage Holdings Corp have been 17% over the past three years , 14% over the past five years .

Back to Top
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett